General Information of Drug (ID: DMJCT6Q)

Drug Name
CD19 CAR T-cells Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Phase 1 [1]
Non-hodgkin lymphoma 2B33.5 Phase 1 [2]
Recurrent adult burkitt lymphoma 2A85.6 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMJCT6Q

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tisagenlecleucel DMM9BJD Acute lymphoblastic leukaemia 2A85 Approved [3]
Blinatumomab DMGECIJ Acute lymphoblastic leukaemia 2A85 Approved [4]
Axicabtagene ciloleucel DMYHN59 Diffuse large B-cell lymphoma 2A81 Approved [5]
Lisocabtagene maraleucel DMP45ME Large B-cell lymphoma 2A81 Approved [6]
Inebilizumab DMI0RHA Neuromyelitis optica spectrum disorder 8E4A.0 Approved [7]
Tecartus DMYQCWT Mantle cell lymphoma 2A85.5 Approved [8]
Loncastuximab tesirine DMXSVGI Diffuse large B-cell lymphoma 2A81 Approved [9]
Obexelimab DMVIC4J IgG4 related disease 4A43.0 Phase 3 [10]
MOR-208 DMDQOWT Diffuse large B-cell lymphoma 2A81 Phase 2/3 [11]
CART-19 DMST3FM Acute lymphoblastic leukaemia 2A85 Phase 2/3 [12]
Tisagenlecleucel DMM9BJD Acute lymphoblastic leukaemia 2A85 Approved [3]
Blinatumomab DMGECIJ Acute lymphoblastic leukaemia 2A85 Approved [4]
Axicabtagene ciloleucel DMYHN59 Diffuse large B-cell lymphoma 2A81 Approved [5]
Lisocabtagene maraleucel DMP45ME Large B-cell lymphoma 2A81 Approved [6]
Inebilizumab DMI0RHA Neuromyelitis optica spectrum disorder 8E4A.0 Approved [7]
Tecartus DMYQCWT Mantle cell lymphoma 2A85.5 Approved [8]
Loncastuximab tesirine DMXSVGI Diffuse large B-cell lymphoma 2A81 Approved [9]
Obexelimab DMVIC4J IgG4 related disease 4A43.0 Phase 3 [10]
MOR-208 DMDQOWT Diffuse large B-cell lymphoma 2A81 Phase 2/3 [11]
CART-19 DMST3FM Acute lymphoblastic leukaemia 2A85 Phase 2/3 [12]
⏷ Show the Full List of 20 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy [2]

References

1 ClinicalTrials.gov (NCT02443831) CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies
2 ClinicalTrials.gov (NCT03298828) CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
3 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
4 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
9 Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
10 Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
11 A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
12 ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL